Personalis opened lower at $15.90, compared with its previous close of $15.96. In the last trading session, the stock traded between $15.81 and $15.95. It showed a sideways intraday trend.
An investment of $100 made 5 years ago in Personalis is now worth
$ 83.56
Resulting in a loss of
$ 16.44 (16.44%)
Note: Past profits do not guarantee future returns.
Rating from 3 Analysts
Today's Change
$-0.10 (-0.63%)
Day High
$15.95
Day Low
$15.81
Day Open
$15.90
Prev Close
$15.96
Volume
17,14,280
1W Return
0.42%
1M Return
0.32%
3M Return
13.08%
6M Return
174.38%
1Y Return
87.90%
Market Cap ($ Mn)
1,719
PE Ratio
-
PB Ratio
7.72
PEG Ratio
-
ROE
-39.31%
ROCE
-36.42%
EPS (TTM)
$-0.31
1 Week
0.42%
1 Month
0.32%
3 Months
13.08%
6 Months
174.38%
9 Months
78.19%
BFA Law probes Personalis $16.25 merger for fiduciary breaches
BFA Law investigates Personalis' $16.25 per share merger with Tempus AI. Inquiry focuses on fiduciary duty breaches and fair value assessment. Tempus AI holds 12.5% stake and has been a commercial partner since 2023. Shareholders advised to review legal options under contingency fee basis.
YesterdayPersonalis Q3 Results: EPS misses estimate, revenue beats by 17%
Loss per share of $(0.32) missed the $(0.25) analyst estimate by 28%. Quarterly sales of $25.596 million beat the $21.850 million estimate by 17.14%. Revenue increased 80.32% YoY from $14.195 million in the prior year period. Loss per share widened 33.33% YoY from $(0.24).
8 days agoBFA Law probes Personalis merger for fiduciary breaches
BFA Law investigates Personalis merger with Tempus AI for fiduciary breaches. Acquisition price set at $16.25 per share announced on July 20, 2026. Tempus AI held 12.5% stake in Personalis as of March 2026. Investigation focuses on fairness of price given prior commercial ties.
22 days agoPersonalis to present NeXT Personal ctDNA data at ESMO 2026
Personalis to present four studies on NeXT Personal ctDNA test at ESMO 2026. Late-breaking oral presentation covers C-POST Phase 3 trial in cutaneous squamous cell carcinoma. Rapid oral presentation features B-STRONGER-1 study on triple-negative breast cancer MRD detection. Two posters address ctDNA kinetics in advanced cancer and platinum-resistant ovarian cancer outcomes.
22 days agoPersonalis launches real-time variant tracking for NeXT Personal MRD test
Personalis launched Real-Time Variant Tracker for NeXT Personal MRD test on October 20, 2026. Feature tracks resistance and therapeutically targetable variants during monitoring. Includes variants linked to FDA-approved therapies and NCCN guidelines. Previously available via Early Access Program starting January 2026.
23 days agoPersonalis secures $18.3M VA MVP task order effective Sept 2026
Personalis received an $18.3 million task order from the U.S. Department of Veterans Affairs. The order is effective September 30, 2026, contingent on sample receipt and service performance. Cumulative VA MVP contract value for Personalis rises to approximately $243.3 million. The deal supports the VA's Million Veteran Program (VA MVP) initiative.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $717.71 | -0.07% | $2,65,923.04M | 33.49 | |
| $235.31 | -0.34% | $1,65,547.88M | 38.52 | |
| $702.59 | +0.85% | $55,354.26M | 39.00 | |
| $176.95 | -0.52% | $49,887.34M | 30.34 | |
| $319.82 | +2.51% | $46,375.50M | - | |
| $470.90 | -0.97% | $46,282.88M | 104.98 | |
| $274.53 | -0.23% | $45,242.54M | 32.52 | |
| $1,749.01 | -0.14% | $34,787.81M | 31.52 | |
| $212.93 | -0.92% | $32,195.02M | 40.22 | |
| $372.23 | +0.36% | $30,225.08M | 27.72 | |
| $258.69 | +0.10% | $28,460.82M | 25.77 | |
| $154.78 | -0.37% | $20,939.57M | - |
An investment of $100 made 5 years ago in Personalis is now worth
$ 83.56
Resulting in a loss of
$ 16.44 (16.44%)
Note: Past profits do not guarantee future returns.
